| Product (compound) |
Brief title |
Year
|
Official study title |
Lundbeck study identifier |
Other identifier(s): ClinicalTrials.gov, EudraCT |
|---|
| Abilify Maintena® (aripiprazole) |
Aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia |
2015 |
A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia |
14724A |
NCT01795547
2012-002785-12
|
| Abilify Maintena® (aripiprazole) |
Aripiprazole once-monthly in patients with schizophrenia |
2015 |
Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia |
14724B |
NCT01959035
2012-003239-47
|
Azilect®
(rasagiline) |
Rasagiline in cognitive-impairment related depression: Azilect in cognitive-impairment related depression (ACCORDO) |
2014 |
A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson's disease patients. ACCORDO Study (Azilect® in cognitive-impairment related depression) |
12962A |
NCT01055379
2009-011144-19
|
Azilect®
(rasagiline) |
Rasagiline in early Parkinson's disease patients not treated with levodopa in China |
2014 |
Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of rasagiline in early Parkinson's disease patients not treated with levodopa in China |
13485A |
NCT01556165
EudraCT N/A
|
| Brintellix® (vortioxetine) |
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) |
2022 |
Interventional, randomized, double-blind, placebocontrolled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) |
12709A |
NCT02709655
2008-005353-38 |
| Brintellix® (vortioxetine) |
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression (VIVRE) |
2022 |
A randomized, double-blind, parallel-group, active-controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with partial response to SSRI treatment |
18498A |
NCT04448431
2019-002704-41 |
Brintellix®
(vortioxetine) |
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD) (RECONNECT) |
2021 |
Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder |
18314A |
NCT04220996
2019-001325-27
|
Brintellix®
(vortioxetine) |
Study with vortioxetine on emotional functioning in patients with depression (COMPLETE) |
2021 |
Interventional, open-label, flexible-dose study of vortioxetine on emotional symptoms in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment |
17797A |
NCT03835715
2017-004829-33
|
Brintellix®
(vortioxetine) |
Continuation with vortioxetine in child and adolescent patients with major depressive disorder (MDD) from 7 to 17 years of age |
2020 |
Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with major depressive disorder (MDD) from 7 to 17 years of age |
12712B |
NCT03108625
2015-002658-11
|
Brintellix®
(vortioxetine) |
Vortioxetine intravenous infusion at initiation of oral treatment with vortioxetine in patients with depression |
2020 |
Interventional, randomised, double-blind, placebo-controlled study of the efficacy and safety of initial administration of 25 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with major depressive disorder |
17915A |
NCT03766867
2018-000992-34
|
Brintellix®
(vortioxetine) |
Active reference (fluoxetine) fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years with major depressive disorder (MDD) |
2019 |
Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with major depressive disorder (MDD) |
12710A |
NCT02709746
2008-005356-25
|
Brintellix®
(vortioxetine) |
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine (AtWoRC) |
2018 |
Interventional, open-label, single cohort, Canadian study to describe the relationship between cognitive symptoms and work productivity in working adults treated with vortioxetine for Major Depressive Disorder |
15913A |
NCT02332954
EudraCT N/A
|
Brintellix®
(vortioxetine) |
Investigating the Effect of Vortioxetine in Adult ADHD Patients |
2017 |
Interventional, randomised, double-blind, placebo-controlled, fixed-dose study of vortioxetine in adults with Attention Deficit Hyperactivity Disorder (ADHD) |
15996A |
NCT02327013
EudraCT N/A
|
Brintellix®
(vortioxetine) |
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder |
2017 |
Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder |
16903A |
NCT02919501
2015-005081-30
|
Brintellix®
(vortioxetine) |
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder |
2016 |
An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major depressive disorder |
15905A |
NCT02279953
2014-000229-19
|
Brintellix®
(vortioxetine) |
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder |
2016 |
An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder |
15906A |
NCT02279966
2014-000230-34
|
Brintellix®
(vortioxetine) |
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder |
2016 |
An interventional, randomised, double-blind, parallel-group, active-comparator, flexible-dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadequate response to current antidepressant treatment of major depressive disorder |
15907A |
NCT02272517
2014-000231-16
|
Brintellix®
(vortioxetine) |
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder |
2015 |
An open-label study evaluating the pharmacokinetics and tolerability of Lu AA21004 in connection with multiple oral dosing of Lu AA21004 in child and adolescent patients with DSM-IV-TRTM diagnosis of depression or anxiety disorder |
12708A |
NCT01491035
2010-020170-42
|
Brintellix®
(vortioxetine) |
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries |
2014 |
A randomised, double-blind, parallel-group, active-comparator (venlafaxine extended release), fixed-dose study of Lu AA21004 in Major Depressive Disorder in Asian countries |
13926A |
NCT01571453
EudraCT N/A
|
Ebixa®
(memantine) |
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer |
2016 |
Interventional, randomised, double-blind, study to evaluate the safety and tolerability of once daily versus twice daily memantine treatment in patients with dementia of Alzheimer's type and MMSE range 5-18 |
14603A |
NCT02553928
EudraCT N/A
|
Northera®
(droxidopa) |
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy |
2015 |
A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy |
16305A |
NCT01927055
EudraCT N/A
|
Onfi®
(clobazam) |
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome |
2016 |
A multi-site, prospective, open-label, long-term, flexible dose, interventional study to evaluate the safety and tolerability of clobazam as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome |
14362B |
NCT02187809
EudraCT N/A
|
Rexulti®
(brexpiprazole) |
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment |
2016 |
Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adjunctive treatment in patients with major depressive disorder with an inadequate response to antidepressant treatment |
14570A |
NCT01838681
2012-004169-42
|
Rexulti®
(brexpiprazole) |
Brexpiprazole in Patients With Schizophrenia |
2016 |
Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia |
14644B |
NCT01810783
2012-002705-21
|
Rexulti®
(brexpiprazole) |
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder |
2016 |
Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder. |
14767B |
NCT01944969
2012-004169-42
|
Rexulti®
(brexpiprazole) |
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD) |
2016 |
Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose study of brexpiprazole as adjunctive treatment to paroxetine or sertraline in adult patients suffering from post-traumatic stress disorder (PTSD) |
14865A |
NCT01987960
2012-004982-41
|
Rexulti®
(brexpiprazole) |
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment |
2016 |
Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment |
16160A |
NCT02400346
2014-003547-35
|
Rexulti®
(brexpiprazole) |
Brexpiprazole in Patients With Acute Schizophrenia |
2015 |
Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia |
14644A |
NCT01810380
2012-002252-17
|
Rexulti®
(brexpiprazole) |
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder |
2015 |
Interventional, open-label, flexible-dose, exploratory study of brexpiprazole as adjunctive treatment of sleep disturbances in patients with major depressive disorder |
15352A |
NCT01942733
EudraCT N/A
|
Rexulti®
(brexpiprazole) |
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy |
2015 |
Interventional, open-label, flexible-dose, exploratory study of brexpiprazole as adjunctive treatment of irritability in patients with major depressive disorder and an inadequate response to antidepressant therapy |
15353A |
NCT01942785
EudraCT N/A
|
Rexulti®
(brexpiprazole) |
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment |
2014 |
Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment |
14571A |
NCT01837797
2012-001361-32
|
Sabril®
(vigabatrin) |
A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) |
2015 |
A prospective, open-label study of the structure and function of the retina in adult patients with refractory complex partial seizures treated with vigabatrin (Sabril®) |
13098A |
NCT01278173
EudraCT N/A
|
Selincro®
(nalmefene) |
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use |
2016 |
Exploratory, interventional, open-label, fixed dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment |
15871A |
NCT02197598
2014-000413-31
|
Selincro®
(nalmefene) |
Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care |
2016 |
Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of
patients with alcohol dependence in primary care |
15892A |
NCT02195817
2013-004688-30
|
Vyepti®
(eptinezumab) |
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine (RELIEF) |
2021 |
A parallel-group, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of eptinezumab administered intravenously in patients experiencing an acute attack of migraine |
18903A |
NCT04152083
EudraCT N/A
|
Vyepti®
(eptinezumab) |
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL) |
2019 |
An open label phase 3 trial to evaluate the safety of ALD403 administered intravenously in patients with chronic migraine |
19022A |
NCT02985398
EudraCT N/A
|
Vyepti®
(eptinezumab) |
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1) |
2018 |
A Parallel Group Double-Blind Randomized Placebo Controlled Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines |
19016A |
NCT02559895
EudraCT N/A
|
Vyepti®
(eptinezumab) |
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2) |
2018 |
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine |
19020A |
NCT02974153
2016-001306-41
|
Vyepti®
(eptinezumab) |
A Multicenter Assessment of ALD403 in Chronic Migraine |
2017 |
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine |
19015A |
NCT02275117
EudraCT N/A
|
